TICKERNERD
Menu
AMGNAMGNHealthcare · Drug Manufacturers - General

AMGN Stock Forecast: Amgen, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$437
−1.55% on the day

The 34 Wall Street analysts covering Amgen, Inc. hold a median 12-month price target of $395 — -9.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 5 Sept 2026 — among the strongest tenth. The factors read stronger than the Street's target implies. That gap is the story on this page.

Market cap
$236.4B
Ticker Nerd rank
91 / 100
Median analyst target
$395
Analysts covering
34
Revenue$10.1B+9.5% y/y
Operating income$3.5B
Net income$2.4B
Free cash flow$3.5B
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.1%
1M
+12.8%
YTD
+36.3%
1Y
+60.5%
From 52W high
−1.6%
From 52W low
+65.8%
$264
$444
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AMGN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Amgen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Sept 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
98
Quality
96
Value
89
Revisions
87
Momentum
83
Growth
66
Accruals
55
Issuance
46
Size
1

Volatility (98): The share price has been relatively steady.

Issuance (46): The company has been issuing shares or taking on financing, diluting existing holders.

Size (1): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AMGN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AMGN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300$350$400$450Oct 25Jan 26Apr 26Jul 26AMGNHigh $457Median $395Low $230

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says34 analysts
14 Buy16 Hold4 Sell
Low $230Median $395High $457

The green dot is the last close — the median target sits −9.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 11 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Sept 2026Wells FargoMaintainsEqual-Weight$400 → $435
20 Aug 2026Piper SandlerMaintainsOverweight$427 → $457
19 Aug 2026Argus ResearchMaintainsBuy$375 → $460
19 Aug 2026Morgan StanleyMaintainsEqual-Weight$351 → $362
18 Aug 2026Cantor FitzgeraldMaintainsNeutral$350 → $400
18 Aug 2026MizuhoMaintainsNeutral$303 → $352
14 Aug 2026BarclaysMaintainsEqual-Weight$360 → $380
10 Aug 2026GuggenheimMaintainsNeutral—
10 Aug 2026GuggenheimMaintainsNeutral$343 → $388
7 Aug 2026CitigroupMaintainsNeutral—
7 Aug 2026CitigroupMaintainsNeutral$345 → $405
6 Aug 2026BernsteinMaintainsMarket Perform—
6 Aug 2026BernsteinMaintainsMarket Perform$335 → $345
5 Aug 2026B of A SecuritiesMaintainsUnderperform—
5 Aug 2026BairdMaintainsUnderperform—
5 Aug 2026BMO CapitalMaintainsOutperform$400 → $450
5 Aug 2026BMO CapitalMaintainsOutperform—
5 Aug 2026Canaccord GenuityMaintainsHold—
5 Aug 2026Goldman SachsMaintainsBuy—
5 Aug 2026OppenheimerMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AMGN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AMGN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Sept 2026, Amgen, Inc. returned +60.5% against +20.0% for the S&P 500, dividends included.

AMGN vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Oct 25Jan 26Apr 26Jul 26AMGNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AMGN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.8%
Analysts raising
24
Analysts cutting
0
Fundamentals

Amgen, Inc. (AMGN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
27.2×

Cheaper than 29% of US stocks

Price / sales
6.2×

Cheaper than 21% of US stocks

Price / book
20.2×

Cheaper than 5% of US stocks

EV / EBITDA
16.2×

Cheaper than 21% of US stocks

Growth & margins
Revenue growth (YoY)
9.5%

Higher than 51% of US stocks

Earnings growth (YoY)
65.9%

Higher than 79% of US stocks

Gross margin
72.0%

Higher than 84% of US stocks

Operating margin
35.5%

Higher than 90% of US stocks

Net margin
23.0%

Higher than 84% of US stocks

Returns & dividend
Return on equity
91.5%

Higher than 96% of US stocks

Return on assets
8.7%

Higher than 90% of US stocks

Dividend yield
2.3%

Higher than 51% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Amgen, Inc. (AMGN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Amgen, Inc. has a market value of $236.4B and an enterprise value of $279.7B.

  • Revenue in the twelve months to 30 June 2026: $38.1B. The latest quarter grew 9.5% year on year.

  • Net income over the same four quarters: $8.7B, a 23.0% net margin.

  • Diluted earnings per share, trailing twelve months: $16.09.

  • Free cash flow in the twelve months to 30 June 2026: $10.2B.

  • Amgen, Inc. spent $5.3B on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 540.6M.

  • Trailing P/E: 27.2×; forward P/E: 17.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 2.31%, paying out 61% of earnings.

  • Amgen, Inc. employs 31,500 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Sept 2026

Data provided by Twelve Data

Peers

AMGN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - General
CompanyMarket capTKN rank
AMGNAmgen, Inc.$236.4B
91
GILDGilead Sciences, Inc.$187.4B
93
PFEPfizer Inc.$161.8B
79
MRKMerck & Co., Inc.$373.1B
83
BMYBristol Myers Squibb Co.$136.0B
99
ABBVAbbVie, Inc.$453.1B
95
JNJJohnson & Johnson$663.3B
92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Amgen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AMGN news & analysis

Cholesterol drug setback casts doubt over multibillion-dollar race

CNBC · 8 Sept 2026negative

Novartis' experimental cholesterol drug pelacarsen failed to reduce cardiovascular events despite lowering levels of the harmful lipid Lp(a). This setback creates uncertainty for rival Lp(a) drugs being developed by Amgen and Eli Lilly.

Why it matters — An Amgen watcher would care because this failed trial from a competitor raises uncertainty around the prospects of Amgen's own rival Lp(a) drug in the same multibillion-dollar race.

Rep. David Taylor discloses 6 new Congressional stock trades

Finbold · 7 Sept 2026neutral

Rep. David J. Taylor, a Republican from Ohio, disclosed six new congressional stock trades, selling positions in biotech and technology companies while buying shares in a utility, a semiconductor firm, and a regional bank.

Why it matters — Because Taylor sold biotech holdings, an AMGN watcher may consider whether such congressional trading activity reflects on the broader biotech sector.

Novartis Late-Stage Cardiovascular Outcome Study Fails, Stock Down

Zacks Investment Research · 7 Sept 2026neutral

Novartis' late-stage cardiovascular outcome study for pelacarsen failed to reduce cardiovascular events, raising doubts about the drug's prospects and highlighting broader portfolio challenges for the company.

Why it matters — An Amgen watcher may find this relevant as a competitor's cardiovascular drug setback could shift the competitive landscape in that therapeutic area, though no direct impact on Amgen is stated.

Amgen Shares Fall as Novartis' Pelacarsen Misses Phase III Study Goal

Zacks Investment Research · 7 Sept 2026negative

Amgen shares fell after Novartis' pelacarsen missed its Phase III study goal, according to Zacks Investment Research. The setback raised investor concern over whether Amgen's olpasiran can deliver positive Phase III outcome data.

Why it matters — Because olpasiran is an Amgen candidate, a competitor's Phase III failure casts doubt on the outlook for Amgen's own program.

Why Amgen (AMGN) is a Top Growth Stock for the Long-Term

Zacks Investment Research · 7 Sept 2026positive

Zacks Investment Research published a piece highlighting Amgen as a top growth stock for the long term, pointing to its Zacks Style Scores as a way to identify strong, market-beating stocks for investment portfolios.

Why it matters — The article positions Amgen favorably among growth stocks, which may be of interest to investors tracking the company's long-term prospects.

FAQ

Frequently asked questions about AMGN stock

What is the AMGN stock price forecast for 2026-2027?

The 34 Wall Street analysts covering Amgen, Inc. have a median 12-month price target of $395, with estimates ranging from $230 to $457. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is AMGN stock a buy right now?

Of the 34 analysts covering Amgen, Inc., 14 rate it a Buy, 16 a Hold and 4 a Sell. Ticker Nerd's systematic factor model ranks Amgen, Inc. 91 out of 100 across roughly 4,600 US stocks as at 5 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank AMGN?

As at 5 Sept 2026, Amgen, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (98 of 100).

Will AMGN stock go up?

No one can know that. What the data says: the median 12-month target from 34 analysts implies -9.7% from the last close, and Ticker Nerd's factor model ranks Amgen, Inc. 91 out of 100 as at 5 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the AMGN stock forecast for 2030?

No analyst covering Amgen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AMGN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $230 to $457 over the next 12 months.

How has AMGN stock performed over the past year?

Amgen, Inc. returned +60.5% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Amgen, Inc. do?

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics.

What is the latest news on AMGN?

The most recent item we track (CNBC, 8 Sept 2026): "Cholesterol drug setback casts doubt over multibillion-dollar race". Novartis' experimental cholesterol drug pelacarsen failed to reduce cardiovascular events despite lowering levels of the harmful lipid Lp(a). This setback creates uncertainty for rival Lp(a) drugs being developed by Amgen and Eli Lilly.

Company

About Amgen, Inc.

Amgen Inc. is a global biotechnology company that discovers, develops, manufactures, and commercializes human therapeutics. Its current portfolio focuses on serious diseases across oncology, cardiovascular disease, inflammation, bone health, nephrology, and rare diseases, with medicines delivered through biologics such as recombinant proteins and monoclonal antibodies. Amgen works with healthcare providers, hospitals, pharmacies, and wholesalers, serving patients in developed markets worldwide. The company’s role in the financial market is closely tied to its branded biologic medicines and research-driven product pipeline, which support its position as one of the leading independent biotechnology companies. Headquartered in Thousand Oaks, California, Amgen combines large-scale manufacturing and global distribution with a strong emphasis on innovative treatments for conditions with high unmet medical need.

CEO Mr. Robert A. Bradway · 31,500 employees · United States · https://www.amgen.com